Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.
Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. Cicero AFG, et al. Among authors: rizzo m. Nutr Rev. 2017 Sep 1;75(9):731-767. doi: 10.1093/nutrit/nux047. Nutr Rev. 2017. PMID: 28938795 Review.
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.
Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos E. Mikhailidis DP, et al. Among authors: rizzo m. Curr Vasc Pharmacol. 2011 Sep;9(5):533-71. doi: 10.2174/157016111796642661. Curr Vasc Pharmacol. 2011. PMID: 21595628
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary.
Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos E. Mikhailidis DP, et al. Among authors: rizzo m. Curr Vasc Pharmacol. 2011 Sep;9(5):531-2. doi: 10.2174/157016111796642698. Curr Vasc Pharmacol. 2011. PMID: 21595629 Free article. No abstract available.
Clinical benefits of ezetimibe use: is absence of proof, proof of absence?
Gouni-Berthold I, Mikhailidis DP, Rizzo M. Gouni-Berthold I, et al. Among authors: rizzo m. Expert Opin Pharmacother. 2012 Oct;13(14):1985-8. doi: 10.1517/14656566.2012.720974. Epub 2012 Sep 4. Expert Opin Pharmacother. 2012. PMID: 22946714 No abstract available.
2,409 results